News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Painkiller Developers Such as Johnson & Johnson (JNJ), Pfizer Inc. (PFE), and Regeneron Pharmaceuticals, Inc. (REGN) Win FDA Advisory Panel's Backing to Continue Studies



3/13/2012 8:08:47 AM

Pfizer Inc. (PFE), Johnson & Johnson (JNJ), and Regeneron Pharmaceuticals Inc. won the backing of a U.S. advisory panel to continue development of a class of experimental painkillers that have been linked to joint failure. The Food and Drug Administration advisers voted 21-0 today in Silver Spring, Maryland, that the benefits of enhanced pain relief outweigh the risks of the so-called anti-nerve growth factor drugs. The FDA isn’t required to follow the panel’s advice. Studies on the class of drugs, once expected by analysts to generate as much as $11 billion a year, were halted in 2010 after the joint issues were reported. Trials for osteoarthritis and back pain, among other chronic conditions, are on hold while a study in cancer pain is ongoing.

Read at Bloomberg
Read at Fox News
Read at Manufacturing
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES